Business Wire

Mitigating Traffic Congestion and Accidents Using Dahua Smart Traffic Management Solution

13.12.2021 16:45:00 EET | Business Wire | Press release

Share

With rapid global urbanization and seemingly perpetual increase in vehicle ownership every year, improving traffic safety and efficiency has become a tough challenge. According to the assessment of international ITS organizations, an effective intelligent transportation system can help reduce traffic congestion and accidents by 20% and traffic delays by 25%. The Dahua Smart Traffic Management Solution, for example, has been applied in various countries to alleviate traffic problems and provide better driving and commuting experience. Equipped with AI, ANPR, image fusion, AR and robust communication technologies, the Dahua Smart Traffic Management Solution can accurately detect traffic violations and optimize signal control timing based on real-time data.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211213005357/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Traffic enforcement is one of the key focuses of this solution. By deploying traffic cameras with ANPR (e.g. ITC952-AU3F-LZF1640 model), traffic violations such as overspeeding, distracted driving, red light violation, unfastened seatbelt, illegal lane changing, etc. can be accurately detected. It supports recognition of number plates from 100 countries and allows algorithm integration with multiple countries. In addition, this Dahua solution also offers an AR Panoramic Platform that is connected to all frontend devices, and presents new labeling display system. It enables traffic operators to respond to traffic alerts and situations in time.

Another aspect of this solution involves signal control timing optimization based on real-time traffic flow. Powered by a lane-level traffic flow detection system, this solution can cover large scenes to detect multiple parameters such as lane flow, occupancy rate, queue length, traffic density, etc. With real-time data captured and analyzed, the traffic lights will automatically switch based on the time of the day and actual road traffic conditions, effectively mitigating urban traffic congestions. Green wave can be carried out during certain times for quick passage of vehicles. Also, these collected traffic data can help city operators in optimizing road network planning.

Meeting the numerous requirements of present-day traffic management, this solution has been applied in various countries and regions around the globe, including Serbia, Mongolia, Indonesia, and Saudi Arabia. One notable example of its effective implementation is in a country in Central Asia. It was deployed at an intersection where vehicle traffic reaches 170,000-250,000 cars per day. It significantly reduced waiting time, improved traffic efficiency by about 25%, helped enhance traffic flow, and lessened the effects of traffic congestion in the surrounding areas of the intersection.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Dahua PR
PR_Global@dahuatech.com

Zoe Xu (xu_shuyi@dahuatech.com)

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release

TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye